NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00116220,Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer,https://clinicaltrials.gov/study/NCT00116220,,COMPLETED,This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.,NO,Prostate Cancer,DRUG: Flutamide (Eulexin) and Lupron or Zoladex|RADIATION: External Beam Radiotherapy,"To determine if the 2 year freedom from PSA failure is increased in patients receiving total androgen suppression and radiation therapy compared to those patients receiving radiation therapy alone., Years","Evaluate the quality of life of patients receiving total androgen suppression and radiation therapy, Years",,Dana-Farber Cancer Institute,Brigham and Women's Hospital|Saint Anne's Hospital|Beth Israel Deaconess Medical Center|Metro West Medical Center,MALE,"ADULT, OLDER_ADULT",PHASE3,206,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,95-096,1995-09,2001-04,2015-02,2005-06-28,,2022-01-06,"Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States",
